Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 7,396,000 | 20,640,000 | 14,002,300 | 8,419,800 | 2,759,000 |
| Depreciation Amortization | 509,000 | 1,997,000 | 1,411,300 | 941,300 | 463,000 |
| Income taxes - deferred | -1,478,000 | -1,707,000 | -958,900 | -1,460,300 | -392,000 |
| Accounts receivable | N/A | -7,000,000 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | N/A | 10,187,000 | N/A | N/A | N/A |
| Other Working Capital | -1,664,000 | -8,093,000 | 681,500 | -5,627,100 | -3,364,000 |
| Other Operating Activity | 570,000 | 789,000 | -1,547,800 | 2,478,800 | 2,200,000 |
| Operating Cash Flow | $5,333,000 | $16,813,000 | $13,588,400 | $4,752,500 | $1,666,000 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -2,326,000 | -7,841,000 | -5,294,300 | -3,206,600 | -1,510,000 |
| Net Acquisitions | -1,058,000 | N/A | -549,400 | N/A | N/A |
| Purchase Of Investment | -297,000 | -645,000 | -518,000 | -367,900 | -197,000 |
| Sale Of Investment | N/A | 964,000 | 832,000 | 275,900 | N/A |
| Other Investing Activity | -235,000 | -3,450,000 | -2,640,100 | -1,888,600 | -1,646,000 |
| Investing Cash Flow | $-3,916,000 | $-10,972,000 | $-8,169,800 | $-5,187,200 | $-3,353,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 1,775,000 | -4,338,000 | -4,337,600 | -245,900 | -1,849,000 |
| Debt Issued | N/A | 13,167,000 | 13,167,200 | 6,461,000 | 6,461,000 |
| Debt Repayment | -750,000 | -778,000 | -778,100 | -778,100 | N/A |
| Common Stock Repurchased | -2,356,000 | -4,108,000 | -2,600,300 | -1,892,200 | -1,200,000 |
| Dividend Paid | -1,548,000 | -5,384,000 | -4,038,500 | -2,693,300 | -1,346,000 |
| Other Financing Activity | -591,000 | -772,000 | -746,900 | -716,700 | -686,000 |
| Financing Cash Flow | $-3,470,000 | $-2,213,000 | $665,800 | $134,800 | $1,380,000 |
| Exchange Rate Effect | 67,000 | 372,000 | 439,100 | 407,400 | 132,000 |
| Beginning Cash Position | 7,268,000 | 3,268,000 | 3,268,400 | 3,268,400 | 3,268,000 |
| End Cash Position | 5,282,000 | 7,268,000 | 9,791,900 | 3,375,900 | 3,093,000 |
| Net Cash Flow | $-1,986,000 | $4,000,000 | $6,523,500 | $107,500 | $-175,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 5,333,000 | 16,813,000 | 13,588,400 | 4,752,500 | 1,666,000 |
| Capital Expenditure | -2,326,000 | -7,841,000 | -5,294,300 | -3,206,600 | -1,510,000 |
| Free Cash Flow | 3,007,000 | 8,972,000 | 8,294,100 | 1,545,900 | 156,000 |